Paraoxonase1 deficiency in mice is associated with hypotension and increased levels of 5,6-epoxyeicosatrienoic acid

Atherosclerosis

Volumn 222, Issue 1, 2012, Pages 92-98

  Gamliel Lazarovich, Aviva ^a   Abassi, Zaid ^a   Khatib, Soliman ^b   Tavori, Hagai ^a,b   Vaya, Jacob ^b   Aviram, Michael ^a   Keidar, Shlomo ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEL HAI COLLEGE   (Israel)

Author keywords

5,6 EET; Hypertension; Nitric oxide; PON1; RAAS; TRPV4

Indexed keywords

5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; ALDOSTERONE; ANGIOTENSIN II; ARACHIDONIC ACID; ARYLDIALKYLPHOSPHATASE 1; CYCLIC GMP; NITRIC OXIDE; NITRITE; RUTHENIUM RED; VANILLOID RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CALCIUM CELL LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; HIGH SODIUM INTAKE; HYPERPOLARIZATION; HYPERTENSION; HYPOTENSION; IN VITRO STUDY; KIDNEY; MALE; MOUSE; NONHUMAN; POTASSIUM INTAKE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION; VASODILATATION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARYLDIALKYLPHOSPHATASE; BLOOD PRESSURE; HUMANS; HYPOTENSION; MALE; MICE; MICE, KNOCKOUT; SODIUM CHLORIDE, DIETARY; TRPV CATION CHANNELS;

EID: 84859852834     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.01.047     Document Type: Article

References (50)

1. Furlong C.E., Suzuki S.M., Stevens R.C., et al. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact 2010, 187:355-361.
2. Billecke S., Draganov D., Counsell R., et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000, 28:1335-1342.
3. Khersonsky O., Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005, 44:6371-6382.
4. Tavori H., Khatib S., Aviram M., Vaya J. Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity. Bioorg Med Chem 2008, 16:7504-7509.
5. Shih D.M., Xia Y.R., Wang X.P., et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000, 275:17527-17535.
6. Rozenberg O., Rosenblat M., Coleman R., Shih D.M., Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003, 34:774-784.
7. Tward A., Xia Y.R., Wang X.P., et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
8. Rozenberg O., Shih D.M., Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005, 181:9-18.
9. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004, 37:1304-1316.
10. Getz G.S., Reardon C.A. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 2004, 15:261-267.
11. Mackness M., Durrington P.N., Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular diseases. Curr Opin Lipidol 2004, 15:399-404.
12. Marra M., Marchegiani F., Antonicelli R., et al. The PON1192RR genotype is associated with a higher prevalence of arterial hypertension. J Hypertens 2006, 24:1293-1298.
13. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995, 96:3005-3008.
14. Wheeler J.G., Keavney B.D., Watkins H., Collins R., Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004, 363:689-695.
15. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
16. Aharoni A., Gaidukov L., Yagur S., et al. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci USA 2004, 101:482-487.
17. Falck J.R., Schueler V.J., Jacobson H.R., et al. Arachidonate epoxygenase: identification of epoxyeicosatrienoic acids in rabbit kidney. J Lipid Res 1987, 28(7):840-846.
18. Murad F., Waldman S., Molina C., Bennett B., Leitman D. Regulation and role of guanylate cyclase-cyclic GMP in vascular relaxation. Prog Clin Biol Res 1987, 249:65-76.
19. Gamliel-Lazarovich A., Gantman A., Shiner M., et al. Paraoxonase 1 deficiency in mice is associated with reduced steroid biosynthesis: effects on HDL binding, cholesteryl ester accumulation and scavenger receptor type BI expression. Atherosclerosis 2010, 211:130-135.
20. Gao F., Sui D., Garavito R.M., Worden R.M., Wang D.H. Salt intake augments hypotensive effects of transient receptor potential vanilloid. 4. Functional significance and implication. Hypertension 2009, 53:228-235.
21. + channels and sensory nerves. J Hypertens 2010, 28:102-110.
22. Watanabe H., Vriens J., Prenen J., et al. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 2003, 424:434-438.
23. Larsen B.T., Miura H., Hatoum O.A., et al. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 2006, 290:H491-H499.
24. Pomposiello S.I., Quilley J., Carroll M.A., Falck J.R., McGiff J.C. 5,6-Epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR. Hypertension 2003, 42:548-554.
25. Ben-Amor N., Redondo P.C., Bartegi A., et al. A role for 5,6-epoxyeicosatrienoic acid in calcium entry by de novo conformational coupling in human platelets. J Physiol 2006, 570:309-323.
26. O'Shaughnessy K.M., Karet F.E. Salt handling and hypertension. J Clin Invest 2004, 113:1075-1081.
27. Meneton P., Jeunemaitre X., de Wardener H.E., MacGregor G.A. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev 2005, 85:679-715.
28. Earley S., Pauyo T., Drapp R., et al. TRPV4-dependent dilation of peripheral resistance arteries influences arterial pressure. Am J Physiol Heart Circ Physiol 2009, 297:H1096-H1102.
29. Capdevila J.H., Wei S., Yan J., et al. Cytochrome P-450 arachidonic acid epoxygenase. Regulatory control of the renal epoxygenase by dietary salt loading. J Biol Chem 1992, 267:21720-21726.
30. Campbell W.B., Gebremedhin D., Pratt P.F., Harder D.R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996, 78:415-423.
31. Ichikawa K., Konta T., Emi M., et al. Genetic polymorphisms of paraoxonase-1 are associated with chronic kidney disease in Japanese women. Kidney Int 2009, 76:183-189.
32. Yu Z., Xu F., Huse L.M., et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000, 87:992-998.
33. Zeldin D.C., Shouzou W., Falck J.R., et al. Metabolism of epoxyeicosatrienoic acids by cytosolic epoxides hydrolase: substrate structural determinants of asymmetric catalysis. Arch Biochem Biophys 1995, 316:443-451.
34. Marowsky A., Burgener J., Falck J.R., Fritschy J.M., Arand M. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Neuroscience 2009, 163:646-661.
35. Fulton D., Falck J.R., McGiff J.C., Carroll M.A., Quilley J. A method for the determination of 5,6-EET using the lactone as an intermediate in the formation of the diol. J Lipid Res 1998, 39:1713-1721.
36. VanderNoot V.A., VanRollins M. Capillary electrophoresis of cytochrome P-450 epoxygenase metabolites of arachidonic acid. 1. Resolution of regioisomers. Anal Chem 2002, 74:5859-5865.
37. Draganov D.I., Teiber J.F., Speelman A., et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005, 46:1239-1247.
38. VanRollins M., Kaduce T.L., Fang X., Knapp H.R., Spector A.A. Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells. J Biol Chem 1996, 271:14001-14009.
39. Humbert R., Adler D.A., Disteche C.M., et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993, 3:73-76.
40. Gaidukov L., Rosenblat M., Aviram M., Tawfik D.S. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res 2006, 47:2492-2502.
41. Paolisso G., Manzella D., Tagliamonte M.R., et al. The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects. J Clin Endocrinol Metab 2001, 86:1078-1082.
42. Weinberger M.H., Miller J.Z., Luft F.C., Grim C.E., Fineberg N.S. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986, 8(Suppl. II):II-127-II-134.
43. Alderman M.H., Cohen H.W., Sealey J.E., Laragh J.H. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004, 7:1-7.
44. Davis K.A., Crow J.A., Chambers H.W., Meek E.C., Chambers J.E. Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners?. Environ Health Perspect 2009, 117:1226-1231.
45. Wright J.T., Dunn J.K., Cutler J.A., et al. ALLHAT collaborative research group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005, 293:1595-1608.
46. Williams B., Poulter N.R., Brown M.J., et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004, 328:634-640.
47. Khan N.A., Hemmelgarn B., Herman R.J., et al. Canadian Hypertension Education Program. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol 2008, 24:465-475.
48. Besler C., Heinrich K., Rohrer L., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011, 121:2693-2708.
49. Uzun H., Karter Y., Aydin S., et al. Oxidative stress in white coat hypertension; role of paraoxonase. J Hum Hypertens 2004, 18:523-528.
50. Guns P.J., Van Assche T., Verreth W., et al. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis. Br J Pharmacol 2008, 153:508-516.